NDAINJECTIONINJECTABLE
Approved
Dec 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OPTIRAY 160 (ioversol) by Guerbet is x-ray contrast activity [moa]. First approved in 1988.
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPTIRAY 160 (ioversol) is an injectable radiographic contrast agent used to enhance X-ray imaging in diagnostic procedures. It works through X-ray contrast activity to improve visualization of blood vessels and organs during angiography and other radiologic examinations. The drug enables clinicians to obtain clearer diagnostic images for cardiovascular and interventional procedures.
LOE Approaching
Product is nearing loss of exclusivity with moderate competitive pressure (30/100), indicating potential team restructuring and transition planning.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on OPTIRAY 160 offers limited upside in a declining product lifecycle; most career development would focus on defending market share and managing generic transition. Roles in this product are increasingly focused on operational efficiency rather than growth initiatives.
Medical Science LiaisonField Sales Representative
Worked on OPTIRAY 160 at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.